康柏西普治疗增殖性糖尿病视网膜病变患者玻璃体切除术后迟发性玻璃体出血

目的：观察玻璃体腔注射康柏西普治疗增殖性糖尿病视网膜病变(PDR)患者玻璃体切除术后迟发性玻璃体出血(POVCH)的效果。

方法：回顾性分析。纳入PDR患者玻璃体术后发生POVCH患者56例57眼,其中康柏西普组28眼行玻璃体腔内注射0.05mL康柏西普,对照组29眼不进行玻璃体腔内注射康柏西普,观察或使用口服药物治疗。记录患者玻璃体切除前后、玻璃体腔注药前后、POVCH后1mo时及随访结束时最佳矫正视力(BCVA)、玻璃体积血分级、眼压、眼底情况及再次手术(玻璃体腔灌术)情况。并观察POVCH发生时患者血糖、血压及心理等全身情况。

结果：POVCH后1mo时,康柏西普组的BCVA优于对照组(1.26±0.13 vs 1.76±0.20; P=0.04),POVCH发生时及随访结束时两组BCVA无统计学差异(P=0.08,0.24)。玻璃体积血混浊改善程度：康柏西普组显效13眼,有效9眼,无效6眼; 对照组显效11眼,有效3眼,无效15眼,差异有统计学意义(P=0.03)。康柏西普组POVCH眼再次手术率低于对照组(21% vs 51%, P=0.045)。康柏西普组平均玻璃体注药次数为2.24±1.16(1～5)次。随访12～24(平均16.47±3.34)mo。POVCH发生的28眼中,发现眼底纤维血管膜11眼(19%),视网膜新生血管11眼(19%),新生血管性青光眼10眼(18%),虹膜新生血管4眼(7%)。POVCH出血吸收后补充视网膜光凝44眼(77%)。POVCH发生时患者血糖和(或)糖化血红蛋白高、血压异常者43例(75%),情绪激动或劳累者6例(11%)。

结论：玻璃体腔内注射康柏西普可促进PDR患者POVCH积血吸收,提高视力,降低再次玻璃体切除手术的几率,同时也应注意严格控制PDR患者的血糖、血压、精神心理等全身因素。     

Intravitreal bevacizumab injection for recurrent vitreous haemorrhage after diabetic vitrectomy

Purpose: To evaluate the efficacy of intravitreal bevacizumab in treating recurrent vitreous haemorrhage (VH) after diabetic vitrectomy. Methods: Consecutive patients with postoperative recurrent VH ≥ 2 weeks after primary diabetic vitrectomy were treated with intravitreal bevacizumab. Repeated injection was given after 2–3 weeks in case of no obvious blood reabsorption (study group). Consecutive patients with the same complication but without bevacizumab injection served as the control group. Vitreous surgeries in both groups were indicated if no clinical improvement was noted 10–12 weeks after the initial bleeding. Vitreous clear‐up time (VCT), vitreous surgeries and rebleeding rates, and visual acuity changes were compared between both groups. Results: The study group had 20 eyes (20 patients) and the control group had 18 eyes (18 patients). Postoperative VH occurred between 1 and 25 months and between 1 and 18 months, respectively. In the study group, VCT after the first recurrent VH was 6.5 ± 1.5 weeks with 2.2 ± 0.8 injections. Nine cases had ≥ one episode of VH, but no surgery was needed. In the control group, 13 eyes had spontaneous re‐absorption (in 6.4 ± 1.3 weeks); five eyes underwent surgeries; three of the 13 eyes eventually had surgeries after further recurrent VH. The rate of vitreous surgery in the two groups was 0/20 and 8/18 (p = 0.01). The total number of rebleeding was 30 in the study group and 27 in the control group (p = 0.69). Conclusion: Intravitreal bevacizumab treatment may reduce the need of revitrectomy for recurrent vitreous haemorrhage after diabetic vitrectomy.     

Visual and anatomical outcomes following vitrectomy for complications of diabetic retinopathy: the DRIVE UK study

Introduction

End-stage diabetic eye disease is an important cause of severe visual impairment in the working-age group. With the increasing availability of refined surgical techniques as well as the early diagnosis of disease because of screening, one would predict that the prevalence of this condition is decreasing and the visual outcome is improving.

Aim

To study the prevalence and visual outcome following vitrectomy for complications of diabetic retinopathy.

Materials and methods

This study identified the patients who underwent vitrectomy from January 2007 to December 2009 because of diabetes-related complications in South East London. Data collected included baseline demographics, best-corrected visual acuity, indication for the vitrectomy, complication, outcome, and duration of follow-up.

Results

The prevalence of people requiring vitrectomy who are registered in the diabetes register of this region was 2 per 1000 people with diabetes. Vitrectomy was required in 185 eyes of 158 patients during this period. These included 83 Caucasians, 51 Afro-Caribbeans, 17 South Asians, and 7 from other ethnic groups. There were 58 patients with type I diabetes and 100 with type II, with a mean duration of diabetes of 23 and 16.5 years, respectively. The reason for vitrectomy included tractional retinal detachment (TRD) in 109 eyes, non-clearing vitreous haemorrhage (NCVH) in 68 eyes, and other causes in 8 eyes. In all, 50% of the eyes with TRD and NCVH, and 87% of the eyes with NCVH improved by at least three ETDRS lines at 12 months. Poor predictors of visual success included longer duration of diabetes (OR: 0.69), use of insulin (OR: 0.04), presence of ischaemic heart disease (OR: 0.04), delay in surgery (OR: 0.59), and the failure to attend clinic appointments (OR: 0.58). Preoperative use of intravitreal bevacizumab in eyes with TRD undergoing vitrectomy showed a marginal beneficial effect on co-existent maculopathy (P=0.08) and required less laser intervention post procedure, but did not affect the number of episodes of late-onset vitreous haemorrhage post vitrectomy (P=0.81).

Conclusion

Visual outcome has improved significantly in eyes with complications due to diabetic retinopathy compared with the previously reported Diabetic Vitrectomy Study.     

眼内填充在增生型糖尿病视网膜病变合并玻璃体出血玻璃体切割术中的作用

目的　分析眼内填充在增生型糖尿病视网膜病变（ｐｒｏｌｉｆｅｒａｔｉｖｅｄｉａｂｅｔｉｃｒｅｔｉｎｏｐａｔｈｙ,ＰＤＲ）合并玻璃体出血玻璃体切割术中的作用。方法　回顾性分析２０１３年５月至２０１５年５月西安交通大学第二附属医院眼科收治的ＰＤＲ合并玻璃体出血行玻璃体切割术患者的病例资料。术后随访至少１ａ,记录患者一般资料、术前及术后最佳矫正视力、玻璃体内填充物类型、复发性玻璃体出血和视网膜脱离情况。结果　１３０例（１３０眼）患者分无填充物、空气填充和硅油填充３组分析,其中无填充物组４５例（３４．６％）、空气填充组３５例（２６．９％）和硅油填充组５０例（３８．５％）。三组患者复发性玻璃体出血分别为:１１．１％（５／４５）、８．６％（３／３５）和１０．０％（５／５０）。术后１ａ内,三组分别有９７．８％、９４．３％和９２．０％患者未发生视网膜脱离。结论　ＰＤＲ合并玻璃体出血行玻璃体切割术中应用眼内填充物在减少复发性玻璃体出血和避免视网膜脱离方面并没有优势。术中没有视网膜裂孔时应用眼内填充物是不必要的。     

Avastin as an adjunct to vitrectomy in the management of severe proliferative diabetic retinopathy: a prospective case series

Purpose:  Bevacizumab (Avastin) is a monoclonal antibody which targets all isoforms of vascular endothelial growth factor A. Its potent anti-angiogenic effects have been shown to cause regression of neovascularization in proliferative diabetic retinopathy. The aim of this study is to investigate the role of Avastin as an adjunct to vitrectomy in the management of severe diabetic eye disease.
Methods:  Sixteen patients (18 eyes) with severe proliferative diabetic retinopathy were recruited into the study. All eyes underwent a single intravitreal injection of bevacizumab 1.25 mg in 0.05 mL prior to vitrectomy surgery for the management of tractional retinal detachment or vitreous haemorrhage due to severe proliferative diabetic retinopathy.
Results:  At 3 months, seven eyes had visual acuities which were better than baseline, four were unchanged and seven were worse. At 6 months, 14 eyes had visual acuities better than baseline, one was unchanged and three were worse. Seven of the 18 eyes (38.8%) had postoperative rebleeds, six of which required surgical washout.
Conclusion:  Avastin improved the ease of the surgery in these complex eyes and the early results are encouraging. We have found it to be particularly useful in diabetic eyes with traction detachments of short duration in which there is still active neovascularization.     

Reducing the incidence of early postoperative vitreous haemorrhage by preoperative intravitreal bevacizumab in vitrectomy for diabetic tractional retinal detachment

Acta Ophthalmol. 2010: 88: 635–640

Abstract.

Purpose: This study aimed to evaluate whether preoperative intravitreal injection of bevacizumab reduces early postoperative vitreous haemorrhage (VH) in vitrectomy for diabetic tractional retinal detachment. Methods: We conducted a retrospective chart review of a consecutive, interventional case series. This included 29 eyes (27 patients) in the bevacizumab group and 40 eyes (37 patients) in the non‐bevacizumab group. For statistical analysis, each patient was assigned to one of four groups according to the haemostatic modalities used (group 1, none; group 2, only long‐acting gas; group 3, only preoperative intravitreal bevacizumab; group 4, both long‐acting gas and preoperative intravitreal bevacizumab). The primary outcome measure was the incidence of early postoperative VH. The secondary outcome measure was visual acuity (VA) at 1 month. Results: The incidence of early postoperative VH was highest in group 1 (63%), followed by group 2 (21%), group 3 (20%) and group 4 (5%). Group 3 showed the best visual recovery in the first month. All eyes in group 3 reached VA ≥ 1/100 at 1 month after the operation, compared with 44%, 29% and 42% in groups 1, 2 and 4, respectively. Conclusions: Preoperative intravitreal injection of bevacizumab may be useful for reducing early postoperative VH in vitrectomy for diabetic tractional retinal detachment. Eyes receiving preoperative intravitreal bevacizumab without the use of long‐acting gas achieved the best visual recovery at 1 month after the operation.     

23-G微创玻璃体切除术联合超声乳化术治疗早期PDR合并玻璃体积血

目的：探讨23-G微创玻璃体切除术联合超声乳化术治疗早期增生性糖尿病视网膜病变(proliferative diabetic retinopathy,PDR)合并玻璃体积血的临床疗效及其并发症的问题。

方法：回顾性分析2011-01/2013-01因早期增生性糖尿病视网膜病变合并玻璃体积血在我院接受23-G微创玻璃体切除联合超声乳化白内障摘除人工晶状体植入术者48例48眼,记录术前和术后1 mp最佳矫正视力,观察眼压、炎症反应,人工晶状体位置以及眼底病情的变化,随访时间4～18mo。

结果：术后1mo最佳矫正视力,视力提高43眼(90%),视力≥0.12者36眼(75%),视力≥0.3者15眼(31%),手术前后视力差异有显著性(P=0.00)。术后有6眼(13%)低眼压,5眼(10%)发生脉络膜脱离,13眼(27%)出现前房炎症反应,16眼(33%)术后早期高眼压,10眼(21%)术后玻璃体腔出血,术后玻璃体视网膜增生性病变、视网膜脱离、虹膜红变及新生血管性青光眼均未发生。

结论：23-G微创玻璃体切除术联合超声乳化术治疗早期增生性糖尿病视网膜病变是安全有效的。     

Early vitrectomy for fundus-obscuring dense vitreous haemorrhage from presumptive retinal tears

Background Published literature on the management of patients with fundus-obscuring dense vitreous haemorrhage due to presumptive retinal tears is sparse and advocates waiting for spontaneous resolution. Surgery is indicated only when a definite retinal tear or retinal detachment is identified. Methods A retrospective review of all patients who underwent early vitrectomy for vitreous haemorrhage associated with posterior vitreous detachment was carried out. A comparison of initial visual acuity versus final visual acuity after vitrectomy was performed. The number of eyes that were found to have retinal tears and retinal detachment were documented. Initial and final Snellen acuities were used for statistical analysis. Categorical data were analysed using Fisher’s exact test and statistical significance was considered to be p<0.05. Results Sixteen eyes were identified and all these patients presented or were referred soon after the onset of vitreous haemorrhage. Associated ocular pathology (choroidal neovascular membrane, retinal branch vein occlusion, macroaneurysm) was suspected to be the source of the haemorrhage in 4 eyes. Vitrectomy was carried out in 12 eyes soon after presentation (mean time 6.3 days, range 1–28 days). Nineteen retinal breaks were seen in these eyes and 5 eyes had more than two breaks. None of the eyes were found to have proliferative vitreo-retinopathy at the time of surgery. Two eyes needed repeat surgery for new retinal breaks. Excluding the eyes found to have an ocular pathology as the cause of vitreous haemorrhage, the mean visual acuity improved from hand movements to 6/12 (p<0.001). Conclusions Early vitrectomy for spontaneous dense fundus-obscuring vitreous haemorrhage and posterior vitreous detachment is safe. Since the number of patients in this study was small, a prospective randomised controlled study comparing early versus late vitrectomy is needed to see whether early surgery also prevents proliferative vitreoretinopathy formation.     

Combined cataract surgery and vitrectomy for vitreous haemorrhage secondary to age-related macular degeneration

Purpose: To report on the functional outcome of surgery on patients with concurrent cataract and breakthrough vitreous haemorrhage from age‐related macular degeneration (ARMD). Methods: Retrospective case series. Results: Five eyes were included in the study. The post operative follow‐up interval ranged from 9 to 12 months. Preoperative visual acuity ranged from hand motion to perception of light. Two surgeries were complicated by iatrogenic breaks, and a further surgery was required to re‐attach the retina in one of these eyes. Only one of the five eyes experienced an improvement in visual functioning. Conclusion: In this series, the outcome of surgery for combined cataract and breakthrough vitreous haemorrhage, secondary to ARMD was poor. The functional outcome of surgery for combined cataract and vitreous haemorrhage secondary to ARMD in this series was poor.     

Vitreous hemorrhage after vitrectomy for diabetic retinopathy

The records of 596 consecutive vitrectomy cases performed for complications of diabetic retinopathy were reviewed to determine the incidence of intraoperative and postoperative vitreous hemorrhage and to determine if blood cleared more rapidly in aphakic compared to phakic eyes. Uncontrollable intraocular bleeding occurred in two eyes (0.5%). Vitreous hemorrhage was present on the first postoperative day in 278 eyes (63%). This early hemorrhage cleared in an average of 9.1 weeks in phakic eyes and 3.4 weeks in aphakic eyes. Further vitreous hemorrhage occurred in 88 eyes (23%). Sixty-four percent of later hemorrhages occurred in 88 eyes (23%). Sixty-four percent of later hemorrhages occurred within six months of the operation and 80% occurred within one year. Later vitreous hemorrhage cleared in an average of 16.2 weeks in phakic eyes and 5.3 weeks in aphakic eyes. Of the 311 eyes with vitreous hemorrhage at some time during the postoperative course, twenty-nine eyes (9%) underwent reoperation to remove nonclearing blood. Nonclearing vitreous hemorrhage was the main cause of final visual loss in only 15 (3.4%) of 438 eyes with adequate follow-up, and 6 of these 15 eyes had final vision of 5/200 or better.     

Association of preoperative vitreous IL‐8 and VEGF levels with visual acuity after vitrectomy in proliferative diabetic retinopathy

Acta Ophthalmol. 2010: 88: e311–e316

Abstract.

Purpose: To determine whether the vitreous levels of interleukin 8 (IL‐8) and vascular endothelial growth factor (VEGF) of patients with proliferative diabetic retinopathy (PDR) were associated with poor visual acuity after vitrectomy. Methods: Observational cross‐sectional study. Patient clinical characteristics and preoperative eye characteristics (63 eyes): visual acuity, iris neovascularization, vitreous haemorrhage, macular detachment, macular oedema, active retinal neovascularization, neovascularization of the disc, burned out PDR (defined as natural end stage of PDR with inactive membranes without previously performed laser photocoagulation) and panretinal photocoagulation were registered prior to vitrectomy for each patient. Vitreous VEGF and IL‐8 levels were measured using the cytometric bead array method. Poor postoperative visual acuity was defined as visual acuity of <20/200 and was checked 2 years after vitrectomy. Results: Twenty‐one of the 63 eyes (33.3%) had poor visual acuity after vitrectomy. Univariate analysis showed that vitreous levels of IL‐8, the absence of panretinal photocoagulation, preoperative macular detachment and poor preoperative visual acuity were significantly associated with poor final visual acuity after vitrectomy. A stepwise multiple logistic regression analysis showed that elevated vitreous levels of IL‐8 (p < 0.0001), macular detachment (p = 0.011) and the absence of panretinal photocoagulation (p = 0.03) were independent predictors for poor visual outcome. Conclusions: Elevated vitreous IL‐8 level could either be a marker of ischaemic inflammatory reaction, or it could play a role in deteriorating visual acuity by DR progression or both. Further studies are needed to provide better understanding of IL‐8 and inflammation involvement in visual prognosis in PDR.     

Association between severity of vitreous haemorrhage and visual outcome in primary rhegmatogenous retinal detachment

Purpose: To elucidate the relationship between the severity of vitreous haemorrhage (VH) and visual outcome in primary rhegmatogenous retinal detachment (RRD) without previous vitreoretinal surgery. Methods: We carried out a retrospective review of patients presenting with RRD and VH between January 1993 and December 2002. Diabetic retinopathy, retinal vessel occlusion and open‐globe injury patients were excluded. Study patients were separated into group 1 (eyes with mild to moderate VH) and group 2 (eyes with severe VH). Results: Our sample included 71 eyes of 71 patients (mean age 48.0 years, range 7–78 years) (median follow‐up period 19 months, range 12–140 months), of which 21 had mild, 17 had moderate and 33 had severe VH. The mean visual acuity (VA) in logMAR (logarithm of minimum angle of resolution) of the 38 eyes in group 1 improved from 1.90 (Snellen equivalent [SE] 20/1589) to 0.68 (SE 20/96). In the 33 eyes in group 2, mean logMAR VA improved from 2.42 (SE 20/5261) to 1.63 (SE 20/853). Group 2 patients were significantly older (p = 0.002), had longer duration of preoperative haemorrhage (p = 0.004), lower presenting VA (p < 0.001), worse final VA (p < 0.001), and a higher incidence of severe (grade C) proliferative vitreoretinopathy (PVR) (p = 0.002). More eyes in group 2 required silicone oil tamponade, although this was not statistically significant (p = 0.133). The overall recurrence rate of retinal detachment after primary surgery was around 21% in both groups. Conclusions: Rhegmatogenous retinal detachment with severe VH is associated with longer duration of preoperative haemorrhage, a higher incidence of severe PVR and worse visual outcome. Close follow‐up and aggressive surgical interventions are suggested in these patients.     

糖尿病性视网膜病变所致玻璃体积血早期手术的效果

目的:评价增生型糖尿病性视网膜病变(PDR)所致玻璃体积血早期手术的效果。方法:回顾性分析2016年6月至2020年6月甘肃省人民医院玻璃体切除手术治疗PDR所致玻璃体积血73例(78眼)的临床资料。根据玻璃体积血时间分为三组：A组,病程<1个月,28眼;B组,病程为1~3个月,26眼;C组,病程>3个月,24眼。所有...     

影响增殖性糖尿病视网膜病变玻璃体切除术后视力改善的因素

目的:分析影响增殖性糖尿病视网膜病变(PDR)玻璃体切除术后视力改善的因素.方法:回顾性分析.收集2014-01/2014-12在马来西亚吉打州,亚罗士打Sultanah Bahiyah医院收治的PDR行玻璃体切除术病例资料,包括1y内患者统计,基线视力(VA)和LogMAR术后最佳矫正视力.使用IBM SPSS Statistics Version 22.0进行数据分析.结果:共103例患者.平均年龄51.2y.在多变量分析中,每个0 logMAR基线VA的1 logMAR术前正偏差与0.859 logMAR的术后改善相关(P<0.001).同样,术前附着的黄斑与玻璃体切除术后的logMAR视力改善相关(b=0.374,P=0.003).无虹膜新血管和无术后并发症与玻璃体切除术后改善的logMAR视力相关,分别为1.126(P=0.001)和0.377(P=0.005).无长效眼内填充与玻璃体切除术后logMAR视力改善相关,为0.302(P=0.010).结论:玻璃体切除术后与视力改善的相关因素是:术前视力较差,黄斑附着,无虹膜新生血管,无术后并发症和未使用长效眼内填充物.了解视力改善的因素将有助于玻璃体视网膜手术的决策.     

Jamming of 25‐gauge instruments in the cannula during vitrectomy for vitreous haemorrhage

Purpose: To report the jamming of 25‐gauge instruments in the cannula during vitreous surgery for non‐clearing vitreous haemorrhage. Methods: Forty‐five eyes underwent vitrectomy with 25‐gauge instruments for non‐clearing vitreous haemorrhage (VH group). The incidence of 25‐gauge instruments jamming in the cannula was determined retrospectively and compared with that in 112 eyes that underwent vitrectomy for epiretinal membrane (ERM group), also using 25‐gauge instruments. Results: The 25‐gauge vitreous cutter or light pipe became jammed in the cannula in three eyes (7%) in the VH group and the instrument locked inside the cannula had to be removed with the cannula. None of the 25‐gauge instruments in the ERM group jammed (p = 0.022, Fisher's exact probability test). Two of three eyes developed giant retinal breaks near the sclerotomy but no retinal break related to the sclerotomy was detected in the ERM group. Examination of the cutter revealed blood trapped between the cutter and the cannula. Conclusions: Twenty‐five gauge instruments may become jammed in the cannula in eyes with non‐clearing vitreous haemorrhage. Clinicians should be aware of this surgical complication when 25‐gauge instruments are used in vitreous haemorrhage.     

玻璃体手术治疗严重增生性糖尿病视网膜病变合并视网膜脱离的效果

目的探讨玻璃体手术治疗严重的增生性糖尿病视网膜病变合并视网膜脱离的疗效及影响视力预后的因素。设计回顾性病例系列。研究对象北京同仁医院2004年3月-2007年3月间行玻璃体手术治疗的87例(95眼)糖尿病视网膜病变Ⅵ期患者。方法回顾上述患者住院病历,均采用传统的三通道玻璃体手术治疗,术后平均随访时间26个月,观察术后视力及眼部并发症发生情况,分析影响视力预后的相关因素。主要指标视力及眼部并发症。结果术后83眼(87%)视网膜复位。视力较术前提高44眼(46.3%),不变16眼(16.8%),下降35眼(36.8%)。手术前后视力差异有统计学意义(P=0.012)。其中60眼视网膜脱离累及黄斑,术后45%的眼视力下降。术后继发新生血管性青光眼7眼(7.4%),角膜失代偿1眼(1.1%),晶状体混浊加重52眼(54.7%)。结论玻璃体切除术治疗严重的增生性糖尿病视网膜病变合并视网膜脱离是有效的,视网膜脱离是否累及黄斑是影响视力预后的最重要的因素。     

伴有增殖型糖尿病视网膜病变的1型糖尿病孕妇的不良结局

目的:报道伴有增殖型糖尿病视网膜病变的糖尿病孕妇,在给予适当的治疗与随访后,产妇和胎儿的不良结局。方法:对患有 1 型糖尿病及增殖型糖尿病视网膜病变的四位年轻的糖尿病孕妇( 年龄 20 ～25 岁) ,进行随访观察。结果:孕妇的不良后果: 流产 1 例,先兆子痫及早产 1 例,肾功能衰竭需要透析 1 例; 胎儿的不良后果: 新生儿死亡1 例,早产婴儿 1 例。结论:对于糖尿病孕妇出现增殖型视网膜病变时,妇产科医生应该给予紧密的随访。对于患有糖尿病的妇女,在其妊娠期间的产前检查与随访中,增殖型糖尿病视网膜病变应当作为疾病的评估之一。     

玻璃体内注射雷珠单抗联合玻璃体切割术治疗严重增生型糖尿病视网膜病变

目的　观察玻璃体内注射雷珠单抗联合玻璃体切割术治疗严重增生型糖尿病视网膜病变（ｐｒｏｌｉｆｅｒａｔｉｖｅｄｉａｂｅｔｉｃｒｅｔｉ-ｎｏｐａｔｈｙ,ＰＤＲ）的临床效果。方法　将临床确诊为严重ＰＤＲ的患者５２例７２眼纳入本研究。依据术前是否行玻璃体内注射雷珠单抗将患者分为治疗组和对照组:治疗组３０例４２眼、对照组２２例３０眼。治疗组术前３ｄ玻璃体内注射１０ｇ·Ｌ－１雷珠单抗０．０５ｍＬ（０．５ｍｇ）,然后行玻璃体切割术,对照组直接行玻璃体切割术。术后随访３～１２（６．５±１．３）个月。对比分析两组患者视力、眼压、黄斑中心凹视网膜厚度和术后并发症的发生情况。结果　治疗组、对照组手术后视力分别为０．０９０±０．０６８、０．０６０±０．０２９,均较术前提高,２组治疗前、治疗后视力比较差异均有统计学意义（ｔ＝－５．００５、－３．２３７,均为Ｐ＜０．０５）。两组术后视力比较,差异有统计学意义（ｔ＝２．０３４,Ｐ＜０．０５）。治疗组、对照组术后黄斑中心凹视网膜厚度分别为（３１３．８±２７．３）μｍ、（３２５．６±１４．５）μｍ,差异有统计学意义（ｔ＝－１．５１,Ｐ＜０．０５）。术后２周、１个月、３个月,治疗组玻璃体积血发生率分别为１２％、２％、２％,对照组发生率分别为２７％、２０％、３％;两组术后各时间点发生率比较,术后２周及１个月之间差异均有统计学意义（χ２＝３．４２、３．２１,均为Ｐ＜０．０５）,术后３个月差异无统计学意义（χ２＝１．０２,Ｐ＞０．０５）。结论　玻璃体切割术联合玻璃体内注射雷珠单抗治疗严重ＰＤＲ能提高患者视力,降低术后玻璃体积血发生率和黄斑中心凹视网膜厚度。     

Adverse outcomes in type 1 diabetic pregnant women with proliferative diabetic retinopathy

AIM: To report maternal and fetal adverse outcomes, in spite of appropriate treatment and regular follow up, in diabetic pregnant women with proliferative diabetic retinopathy. METHODS: Case series of four young pregnant diabetics aged between 20 and 25 years with type 1 diabetes mellitus and proliferative diabetic retrinopathy. RESULTS: The maternal adverse outcomes were abortion in one patient, pre-eclampsia and preterm delivery in one patient, and renal failure requiring dialysis in one patient. The fetal adverse outcomes were neonatal death in one case and premature baby in another case. CONCLUSION: These cases highlight the fact that diabetic pregnant women should be closely followed up by the obstetricians and physicians when they have proliferative retinopathy. The proliferative diabetic retinopathy should be considered as a part of the assessment when counseling a diabetic woman in antenatal check up and also in the follow up visits during pregnancy.     

术毕注射康柏西普联合25G玻璃体切割术治疗早期PDR合并玻璃体积血

目的:分析探讨手术结束时玻璃体腔注射康柏西普联合25G微创玻璃体切割手术(PPV)在治疗早期增殖性糖尿病视网膜病变(PDR)合并玻璃体积血的有效性和安全性。方法:回顾性研究分析就诊于南京医科大学眼科医院患有PDR合并有玻璃体积血需要行平坦部PPV患者60例60眼。依据患者注药时间分为术毕联合康柏西普注射组(A组)20例20眼、术前康柏西普注射组(B组)20例20眼和无注射(C组)20例20眼三组进行观察分析,分析三组患者的手术前后视力、眼压、术中情况、术后预后及并发症的差异。结果:三组患者的手术前基本情况及手术时间均无差异,三组术中均未出现医源性裂孔、硅油填充,术后均未出现复发性视网膜脱离。三组术后1、3、6mo最佳矫正视力(BCVA)均较术前改善(P<0.05),注射组(A组和B组)术眼术后BCVA改善程度均优于无注射组(C组),均有差异(P<0.05)。A组术后晚期玻璃体积血(术后1mo之后)发生率明显低于B组和C组(均P<0.05)。注射组(A组和B组)术眼中央视网膜厚度在术后1、3、6mo均低于无注射组(C组),均有差异(P<0.05)。结论:术毕注射康...